GSK’s respiratory syncytial virus
The Pharma Data
APRIL 27, 2023
1 If approved, GSK’s candidate has the potential to be the first vaccine available to help protect older adults from RSV disease. The most frequently observed solicited adverse events were injection site pain, fatigue, myalgia, headache, and arthralgia. Efficacy was 94.6% (95% CI, 65.9–99.9,
Let's personalize your content